180 related articles for article (PubMed ID: 21251700)
1. DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.
Zeimet AG; Fiegl H; Goebel G; Kopp F; Allasia C; Reimer D; Steppan I; Mueller-Holzner E; Ehrlich M; Marth C
Gynecol Oncol; 2011 Apr; 121(1):24-31. PubMed ID: 21251700
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
Notaro S; Reimer D; Fiegl H; Schmid G; Wiedemair A; Rössler J; Marth C; Zeimet AG
BMC Cancer; 2016 Aug; 16():589. PubMed ID: 27485273
[TBL] [Abstract][Full Text] [Related]
3. DNA hypomethylation and ovarian cancer biology.
Widschwendter M; Jiang G; Woods C; Müller HM; Fiegl H; Goebel G; Marth C; Müller-Holzner E; Zeimet AG; Laird PW; Ehrlich M
Cancer Res; 2004 Jul; 64(13):4472-80. PubMed ID: 15231656
[TBL] [Abstract][Full Text] [Related]
4. Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia.
Pradjatmo H
Asian Pac J Cancer Prev; 2015; 16(18):8599-604. PubMed ID: 26745123
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of folate binding protein in ovarian cancers.
Toffoli G; Cernigoi C; Russo A; Gallo A; Bagnoli M; Boiocchi M
Int J Cancer; 1997 Apr; 74(2):193-8. PubMed ID: 9133455
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary.
Bakshi N; Rajwanshi A; Patel F; Ganguly NK
Anal Quant Cytol Histol; 1998 Jun; 20(3):215-20. PubMed ID: 9642449
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P
Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547
[TBL] [Abstract][Full Text] [Related]
10. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
Lassus H; Staff S; Leminen A; Isola J; Butzow R
Gynecol Oncol; 2011 Jan; 120(1):11-7. PubMed ID: 20937525
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
12. Identification by cDNA microarray of genes involved in ovarian carcinogenesis.
Ono K; Tanaka T; Tsunoda T; Kitahara O; Kihara C; Okamoto A; Ochiai K; Takagi T; Nakamura Y
Cancer Res; 2000 Sep; 60(18):5007-11. PubMed ID: 11016619
[TBL] [Abstract][Full Text] [Related]
13. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Karlsson M; Seidal T
Int J Oncol; 2001 Dec; 19(6):1295-302. PubMed ID: 11713603
[TBL] [Abstract][Full Text] [Related]
14. Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.
Wimberger P; Chebouti I; Kasimir-Bauer S; Lachmann R; Kuhlisch E; Kimmig R; Süleyman E; Kuhlmann JD
Gynecol Oncol; 2014 Jun; 133(3):467-72. PubMed ID: 24713547
[TBL] [Abstract][Full Text] [Related]
15. beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients.
Kildal W; Risberg B; Abeler VM; Kristensen GB; Sudbø J; Nesland JM; Danielsen HE
Eur J Cancer; 2005 May; 41(8):1127-34. PubMed ID: 15911235
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia upregulates ovarian cancer invasiveness via the binding of HIF-1α to a hypoxia-induced, methylation-free hypoxia response element of S100A4 gene.
Horiuchi A; Hayashi T; Kikuchi N; Hayashi A; Fuseya C; Shiozawa T; Konishi I
Int J Cancer; 2012 Oct; 131(8):1755-67. PubMed ID: 22287060
[TBL] [Abstract][Full Text] [Related]
17. Alu and Satα hypomethylation in Helicobacter pylori-infected gastric mucosae.
Yoshida T; Yamashita S; Takamura-Enya T; Niwa T; Ando T; Enomoto S; Maekita T; Nakazawa K; Tatematsu M; Ichinose M; Ushijima T
Int J Cancer; 2011 Jan; 128(1):33-9. PubMed ID: 20602342
[TBL] [Abstract][Full Text] [Related]
18. Frequent aberrant methylation of the imprinted IGF2/H19 locus and LINE1 hypomethylation in ovarian carcinoma.
Dammann RH; Kirsch S; Schagdarsurengin U; Dansranjavin T; Gradhand E; Schmitt WD; Hauptmann S
Int J Oncol; 2010 Jan; 36(1):171-9. PubMed ID: 19956846
[TBL] [Abstract][Full Text] [Related]
19. DNA hypomethylation is prevalent even in low-grade breast cancers.
Jackson K; Yu MC; Arakawa K; Fiala E; Youn B; Fiegl H; Müller-Holzner E; Widschwendter M; Ehrlich M
Cancer Biol Ther; 2004 Dec; 3(12):1225-31. PubMed ID: 15539937
[TBL] [Abstract][Full Text] [Related]
20. [A quantitative study on nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma].
Liu C; Zhao Y; Sun X
Zhonghua Fu Chan Ke Za Zhi; 1995 Dec; 30(12):738-40. PubMed ID: 8728920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
